Insider Selling: Arvinas, Inc. (NASDAQ:ARVN) Insider Sells 9,020 Shares of Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the sale, the insider now directly owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Arvinas Trading Up 5.5 %

ARVN stock opened at $17.67 on Wednesday. The firm has a market cap of $1.21 billion, a P/E ratio of -6.38 and a beta of 1.88. Arvinas, Inc. has a 1-year low of $16.07 and a 1-year high of $51.51. The business’s 50 day moving average is $18.41 and its 200-day moving average is $22.80.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the company posted ($2.53) EPS. Sell-side analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in shares of Arvinas in the 4th quarter worth approximately $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Arvinas by 0.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock worth $8,311,000 after buying an additional 3,047 shares in the last quarter. Voloridge Investment Management LLC acquired a new position in Arvinas during the 4th quarter worth $749,000. Woodline Partners LP lifted its holdings in Arvinas by 39.2% during the 4th quarter. Woodline Partners LP now owns 692,733 shares of the company’s stock worth $13,280,000 after buying an additional 194,996 shares in the last quarter. Finally, Twinbeech Capital LP acquired a new position in Arvinas during the 4th quarter worth $3,146,000. 95.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ARVN shares. HC Wainwright reissued a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research report on Wednesday, December 11th. Wedbush reissued an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research report on Tuesday, February 11th. BTIG Research started coverage on Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective for the company. Guggenheim reissued a “buy” rating and set a $57.00 price objective on shares of Arvinas in a research report on Wednesday, February 12th. Finally, Oppenheimer boosted their price target on Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Arvinas presently has a consensus rating of “Buy” and a consensus target price of $60.00.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.